quantisnow
FeedTopReportsPricing
⌘K
Live feed
04:43:10·568d
FDARegulatory
Delcath Systems Inc. logo

FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

DCTH· Delcath Systems Inc.
Health Care
Original source

Companies

  • DCTH
    Delcath Systems Inc.
    Health Care

Recent analyst ratings

  • Jun 28UpdateCraig Hallum$18.00
  • May 14UpdateStephens$25.00
  • Jul 26UpdateCanaccord Genuity$17.00
  • Dec 10UpdateH.C. Wainwright$25.00

Related

  • PR13h
    Delcath Systems to Host First Quarter 2026 Earnings Call
  • PR17d
    Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
  • SEC21d
    SEC Form DEFA14A filed by Delcath Systems Inc.
  • SEC21d
    SEC Form DEF 14A filed by Delcath Systems Inc.
  • INSIDER48d
    Chief Financial Officer Pennell Sandra bought $50,018 worth of shares (5,533 units at $9.04), increasing direct ownership by 8% to 77,018 units (SEC Form 4)
  • SEC51d
    SEC Form 8-K filed by Delcath Systems Inc.
  • INSIDER51d
    CHIEF EXECUTIVE OFFICER Michel Gerard J bought $100,309 worth of shares (11,200 units at $8.96), increasing direct ownership by 3% to 342,034 units (SEC Form 4)
  • PR51d
    Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022